Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GALR2 | O43603 | 1/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375798 | 0.90 | MAPT (0.45) | NPSR1MAPTALDH1A1HTTKMT2A | |
| SCHEMBL22463095 | 0.90 | MAPT (0.45) | NPSR1MAPTALDH1A1HTTKMT2A | |
| SCHEMBL22463108 | 0.84 | AR (0.41) | MAPTALDH1A1KMT2A | |
| SCHEMBL7652191 | 0.83 | BAZ2B (0.44) | NPSR1MAPTALDH1A1POLBBAZ2B | |
| SCHEMBL7154811 | 0.82 | MAPT (0.50) | NPSR1MAPTALDH1A1HTTKMT2A | |
| SCHEMBL7653960 | 0.80 | BAZ2B (0.42) | MAPTALDH1A1HTTKMT2APOLB | |
| SCHEMBL7654012 | 0.78 | MAPT (0.41) | MAPTALDH1A1HTTKMT2APOLB | |
| SCHEMBL7653318 | 0.78 | BAZ2B (0.40) | MAPTALDH1A1KMT2ABAZ2BHPGD | |
| SCHEMBL7658479 | 0.78 | BRD4 (0.41) | MAPTALDH1A1HTTPOLBBAZ2B | |
| SCHEMBL4657132 | 0.77 | TSHR (0.42) | MAPTALDH1A1HTTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051463-A1 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2025-02-13 | — | — | US | disclosed |
| WO-2025027472-A2 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2025-02-06 | — | — | WO | disclosed |
| CN-117263948-B | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| CN-118240003-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118221763-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-113631196-B | Compounds and conjugates thereof | 免疫医疗有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117263948-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-11795225-B2 | Therapeutic binding molecules | MEDIMMUNE LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| CN-116829592-A | Therapeutic B7-H4 binding molecules | 免疫医疗有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3946464-B1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LTD (GB) | 2022-08-31 | — | — | EP | disclosed |
| CN-114980934-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220211863-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| WO-2022053650-A1 | THERAPEUTIC B7-H4 BINDING MOLECULES | MEDIMMUNE LIMITED (GB) | 2022-03-17 | — | — | WO | disclosed |
| EP-3946464-A1 | COMPOUNDS AND CONJUGATES THEREOF | MedImmune Limited (GB) | 2022-02-09 | — | — | EP | disclosed |
| CN-113631196-A | Compounds and conjugates thereof | 免疫医疗有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-20210322401-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2021-10-21 | — | — | US | disclosed |
| WO-2020200880-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-08 | — | — | WO | disclosed |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-10-01 | — | — | US | disclosed |
| US-5061795-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211863-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | NPSR1 4447/4885MAPT 1295/4885ALDH1A1 1742/4885 |
| US-11795225-B2 | Therapeutic binding molecules | EPCAM, IGSF11, FCGR3B | NPSR1 1926/4885MAPT 1237/4885ALDH1A1 1539/4885 |
| US-20200306243-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | NPSR1 4447/4885MAPT 1295/4885ALDH1A1 1742/4885 |
| US-20240239894-A1 | THERAPEUTIC BINDING MOLECULES | EPCAM, IGSF11, FCGR3B | NPSR1 1926/4885MAPT 1237/4885ALDH1A1 1539/4885 |
| US-20250051463-A1 | CD123 ANTIBODY-DRUG CONJUGATES AND METHODS OF USING THE SAME | IL23R, CD63, CD2 | NPSR1 3213/4885MAPT 3882/4885ALDH1A1 928/4885 |
| US-20210322401-A1 | COMPOUNDS AND CONJUGATES THEREOF | TOP2A, TOP1, TOP2B | NPSR1 4447/4885MAPT 1295/4885ALDH1A1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.